GlassScriptPhysician profile
Stephen Adrian Quarterman
NPI 1427100254
$5,594.29
in general payments reported to CMS, 2019-2025
26 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $883 · 2023: $1,661 · 2024: $1,569 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,107 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.89 |
| Education | $274.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,001.04 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $851.73 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $756.99 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $553.16 | 2022-2025 | Ilumya |
| Incyte Corporation | $420.89 | 2021-2025 | Opzelura |
| Ucb, INC. | $278.07 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $261.33 | 2022-2025 | Otezla, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $173.60 | 2022-2025 | |
| Leo Pharma INC. | $144.69 | 2022-2023 | Adbry |
| Pfizer INC. | $144.11 | 2022-2025 | |
| Biofrontera INC. | $139.44 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Genzyme Corporation | $126.87 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.61 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $109.25 | 2021-2024 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.15 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $79.21 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $77.13 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $73.71 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $59.15 | 2023-2025 | Zoryve |
| Organogenesis INC. | $29.36 | 2022-2024 | |
| Organon LLC | $27.94 | 2025 | Hadlima |
| Almirall LLC | $25.30 | 2023 | Klisyri |
| Botanix Sb INC | $19.87 | 2025 | Sofdra |
| Epi Health, LLC | $16.58 | 2022 | |
| Verrica Pharmaceuticals INC. | $13.62 | 2025 | Ycanth |
| Mayne Pharma Commercial LLC | $7.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Quarterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.